Measuring Dietary Iron Absorption From Edible Insects and Assessing the Effect of Chitin Content on Iron Bioavailability (Study 2) (Sustironable2)

Measuring Dietary Iron Absorption From Edible Insects and Assessing the Effect of Chitin Content on Iron Bioavailability: Stable Iron Isotope Studies in Young Women (Study 2, Xylotrupes Gideon)

Due to the growing world population, there is a need to develop viable ecological and nutritional alternatives to animal food products. However, animal products are a key dietary source of well-absorbed iron, and iron deficiency and iron deficiency anemia remain highly prevalent in high- and low-income countries. Meat and fish provide a substantial proportion of absorbed iron in the western diet by two distinct components: a) heme iron is well absorbed (20-45% fractional absorption) and is not affected by most dietary enhancers and inhibitors, which often affect non-heme iron absorption; b) peptides in muscle meat exert an enhancing effect the absorption of non-heme iron contained in other meal components. The potential of edible insects as a dietary source of well-absorbed iron has not been investigated in detail. In particular, it is unclear whether insects provide an iron moiety similar to hemoglobin which would be well absorbed and unaffected by other dietary components, and whether their presence in a test meal exerts an enhancing effect on iron bioavailability from the whole meal.

To differentiate iron absorption from insect biomass from other sources, insects will be intrinsically labelled with the stable iron isotope 57Fe, while other food iron components will be labelled with the iron isotope 58Fe.The present studiy will provide novel data to elucidate the nutritional value as sources of dietary iron of insect species Xylotrupes gideon. X. gideon is an insect species traditionally widely consumed in SubSaharan Africa and South East Asia and recognised by FAO as an edible insect species. X gideon is produced in ZHAW facilities in Linthal, Switzerland under controlled conditions aiming to a highly sustainable and high nutritional value food product. Furthermore the benefit of ascorbic acid addition to X.gideon biomass on iron absorption will be quantified.

Study Overview

• Status: Enrolling by invitation
• Conditions: Iron-deficiency
• Intervention / Treatment: Other: Bread and butter; Other: X.gideon; Other: X.gideon with ascorbic acid

• Study Type: Interventional
• Enrollment (Anticipated): 11
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Switzerland
  • Zurich, Switzerland, 8092
    • ETH Zurich, Laboratory of Human Nutrition

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 45 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Female, 18 to 45 years old
• Normal Body Mass Index (18.5 - 25 kg/m2)
• Body weight ≤ 55 kg
• Non-anemic (hemoglobin (Hb) >12.0 g/dL)
• Serum Ferritin < 25 μg/L;
• Normal CRP (<5.0 mg/L), indicating no inflammation
• Knowledge of English at least at level B2 (assessed by self-declaration)
• Signed informed consent

Exclusion Criteria:

• Pregnancy (assessed by self-declaration)
• Lactating up to 6 weeks before study initiation
• Any metabolic, gastrointestinal kidney or chronic disease such as diabetes, hepatitis, hypertension, cancer or cardiovascular diseases (according to the participants own statement)
• Continuous/long-term use of medication (except for oral contraceptives and anti-acne medication)
• Consumption of mineral and vitamin supplements within 2 weeks prior to 1st meal administration
• Blood transfusion, blood donation or significant blood loss (accident, surgery) over the past 4 months
• Earlier participation in a study using iron stable isotopes or participation in any clinical study within the last 30 days
• Participant who cannot be expected to comply with study protocol (e.g. not available on certain study appointments
• Cigarette smoking ( > 1 cigarette per day)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Single

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Bread and butter; A toast bread with butter meal without insect biomass with FeSO4 (isotopic iron 54)	Other: Bread and butter; A bread with butter meal without insect biomass with FeSO4 (isotopic iron 54)
Experimental: X.gideon; Intrinsically labelled (57Fe) or non labelled X.gideon flour mixed with butter and sugar meal with FeSO4 (extrinsic label, isotopic iron 58)	Other: X.gideon; Intrinsically labelled (57Fe) or non labelled X.gideon flour mixed with butter and sugar meal with FeSO4 (extrinsic label, isotopic iron 58)
Experimental: X.gideon with ascorbic acid; Intrinsically labelled (57Fe) or non labelled X.gideon flour mixed with butter and sugar meal with FeSO4 (extrinsic label, isotopic iron 58) and ascorbic acid	Other: X.gideon with ascorbic acid; Intrinsically labelled (57Fe) or non labelled X.gideon flour mixed with butter and sugar meal with FeSO4 (extrinsic label, isotopic iron 58) and ascorbic acid

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Fractional Iron absorption	Fractional iron absorption will be calculated based on the shift of the iron isotope ratios in the collected blood samples after the administration of the intervention products .Fractional iron absorption will be measured as erythrocyte incorporation of the naturally occurring iron forms with different masses used to label the iron supplements.	30th day of the study

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Hemoglobin (Hb)	Iron status marker	screening (-1), day 16th and day 30th of the study
Plasma ferritin (PF)	Iron status marker	screening (-1), day 16th and day 30th of the study
C-Reactive Protein (CRP)	Inflammation status	screening (-1), day 16th and day 30th of the study
Soluble transferring receptor (sTfR)	Iron status marker	screening (-1), day 16th and day 30th of the study
Body iron stores (BIS)	Iron status marker	screening (-1), day 16th and day 30th of the study
Alpha 1 acid glycoprotein (AGP)	Inflammation marker	screening (-1), day 16th and day 30th of the study

Collaborators and Investigators

• Sponsor: Swiss Federal Institute of Technology
• Collaborators: Zurich University of Applied Sciences
• Investigators: Principal Investigator: Nikolin Hilaj, MSc, Laboratory of Human Nutrition ETH Zürich

Study record dates

Study Major Dates

• Study Start (Actual): May 20, 2022
• Primary Completion (Anticipated): July 20, 2022
• Study Completion (Anticipated): July 30, 2022

Study Registration Dates

• First Submitted: April 7, 2022
• First Submitted That Met QC Criteria: April 7, 2022
• First Posted (Actual): April 14, 2022

Study Record Updates

• Last Update Posted (Actual): June 10, 2022
• Last Update Submitted That Met QC Criteria: June 9, 2022
• Last Verified: June 1, 2022

More Information

Terms related to this study

• Keywords: ascorbic acid; iron bioavailability; edible insects; Xylotrupes gideon
• Additional Relevant MeSH Terms: Metabolic Diseases; Hematologic Diseases; Anemia, Hypochromic; Anemia; Iron Metabolism Disorders; Anemia, Iron-Deficiency; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Protective Agents; Micronutrients; Vitamins; Antioxidants; Ascorbic Acid
• Other Study ID Numbers: Sust-iron-able2

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No